SureTrader
Nadex Advertisement
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Ra Pharmaceuticals, Inc. (RARX)

RARX RSS Feed
Add RARX Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 5/15/2017 9:32:14 PM - Followers: 1 - Board type: Free - Posts Today: 0

Ra Pharmaceuticals, Inc. 87 Cambridge Park Drive Cambridge Cambridge, MA 02140 United States 617-401-4060 http://www.rapharma.com Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is RA101495, an injection into the tissue under the skin for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), as well as for the treatment of other debilitating complement-mediated diseases, including refractory generalized myasthenia gravis (rMG) and lupus nephritis (LP). The company's preclinical testing products include Factor D inhibition for age-related macular degeneration and geographic atrophy, as well as for Orphan renal dense deposit and C3 glomerulonephritis; Oral C5 inhibitor for PNH, rMG, LN, and central nervous system (CNS) diseases; and C1s inhibition for autoimmune/CNS diseases. It has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.
RARX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
SureTrader
RARX News: Ra Pharmaceuticals Announces Publication of Positive Preclinical Data with RA101295 for the Treatment of Escherichia Coli Sep... 07/19/2017 04:05:00 PM
RARX News: Ra Pharmaceuticals Announces Initial Data from Phase 2 Clinical Trial of RA101495 in PNH 06/27/2017 07:00:00 AM
RARX News: Current Report Filing (8-k) 06/26/2017 04:04:23 PM
RARX News: Ra Pharmaceuticals Presents Data on Oral Small Molecule Complement Inhibitors at the 22nd Congress of the European Hematology... 06/24/2017 11:00:00 AM
RARX News: Statement of Changes in Beneficial Ownership (4) 06/22/2017 07:42:43 PM
PostSubject
#2   Up and up? AD2000 05/15/17 09:32:14 PM
#1   RARX bullish 22.82 stocktrademan 04/16/17 04:04:12 PM
PostSubject